Rabbit Polyclonal SHC2(N-Term) Antibody

+ +

•  

   
     All lanes : Anti-SHC2 Antibody (N-Term) at 1:2000 dilution Lane 1: Human cerebellum lysate Lane 2: U-251 MG whole cell lysate Lane 3: U-87 MG whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 62 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-2 OS (human osteosarcoma cell line) cells labeling SHC2 with P34549 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm and weak nucleus staining on U-2 OS cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red).The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing U-2 OS cells stained with P34549(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34549,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OE188374) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

The SHC2 (N-Term) antibody is a tool for detecting the N-terminal region of SHC-transforming protein 2 (SHC2), a member of the SHC family of adaptor proteins involved in intracellular signaling. SHC proteins, including SHC1. SHC2. SHC3. and SHC4. share conserved domains: an N-terminal phosphotyrosine-binding (PTB) domain, a central collagen-homology (CH1) region, and a C-terminal Src homology 2 (SH2) domain. SHC2 plays a role in transmitting signals from activated receptor tyrosine kinases (RTKs) to downstream effectors, particularly through interactions with GRB2 and SOS1 to activate the Ras-MAPK pathway. It is implicated in neurotrophic signaling, notably via the TrkB receptor, influencing neuronal differentiation, survival, and synaptic plasticity. Dysregulation of SHC2 has been associated with cancer progression and neurological disorders.

The SHC2 (N-Term) antibody specifically targets epitopes near the N-terminus, allowing researchers to study SHC2 expression, post-translational modifications (e.g., tyrosine phosphorylation), and subcellular localization. It is commonly used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate SHC2's role in RTK-mediated pathways, particularly in contexts such as oncogenesis, neural development, and disease models. Validated for reactivity in human, mouse, and rat samples, this antibody is critical for elucidating SHC2's functional diversity compared to other SHC isoforms, which exhibit tissue-specific expression and signaling preferences. Proper controls, including knockout validations, are recommended to confirm specificity due to potential cross-reactivity with homologous regions in related proteins.